CN114763553B - Recombinant vector for improving yield of macrolide antibiotics, recombinant bacterium and application - Google Patents

Abstract

The invention discloses a recombinant vector for improving the yield of macrolide antibiotics, recombinant bacteria and application thereof, belonging to the field of genetic engineering. The invention aims to improve the yield and the potency of macrolide antibiotics. A recombinant vector for the efflux of macrolide antibiotics is prepared from pSET152T as the start vector, the Streptomyces icebergii BC-101-4 genome as template, the promoter and the efflux gene, and the sequence obtained by connecting the promoter with the efflux gene, which is located upstream of the efflux gene, are integrated into the start vector. The recombinant bacterium is constructed through genetic engineering, so that the feedback inhibition effect of the final product is reduced, and the yields of milbemycins, abamectin and Ni Mo Keding are improved in fermentation production.

Description

Recombinant vector for improving yield of macrolide antibiotics, recombinant bacterium and application

Technical Field

The invention belongs to the field of genetic engineering, and in particular relates to a recombinant vector for improving the yield of macrolide antibiotics, recombinant bacteria and application thereof.

Background

Macrolide antibiotics are a class of biologically active secondary metabolites that can be produced by streptomyces, many of which have been used for the large-scale production of biopesticides, such as avermectin, milbemycin, ni Mo Keding, and the like. At present, various strategies are used for constructing industrial strains with high antibiotic yield, however, the increase of the unit fermentation yield leads to a surge of intracellular accumulation of antibiotics, which seriously affects the growth of the strains and the further increase of the yield. It is well known that an increase in the amount of end product accumulation can produce a negative feedback inhibition of the overall synthesis process. In particular, the synthesis amount of antibiotics is greatly increased after fermentation of Streptomyces enters the stationary phase, and this accumulation inhibition phenomenon is particularly serious. The efflux proteins have the important function of maintaining the dynamic balance of intracellular and extracellular substances, and their pumping efficiency on downstream products directly affects the forward reaction efficiency of the precursor substances. Thus, the ability of the host bacteria to excrete antibiotics throughout the fermentation process, particularly at the late stages of fermentation, directly affects the rate of synthesis of the final product and the final yield. Moreover, the difficulty in separating and extracting antibiotics can be effectively reduced by increasing the excretion of the target product, so that the adaptation of the excretion path is of great significance for further improving the unit yield of the antibiotics of the industrial strain.

Disclosure of Invention

The invention aims to improve the yield and titer of macrolide antibiotics, and provides a recombinant vector for improving the yield of macrolide antibiotics, wherein the starting vector of the recombinant vector is pSET152T, a promoter and an efflux gene are amplified by taking a Streptomyces icebergii (Streptomyces bingchenggensis) BC-101-4 genome as a template, and an efflux module obtained by connecting the promoter and the efflux gene is integrated into the starting vector, so that the recombinant vector is obtained, and the promoter is positioned at the upstream of the efflux gene.

Further defined, the promoter comprises a sequence of 5'-GAGAGA-3' with the sequence of P1 sequence SEQ ID NO:1, P2 sequence SEQ ID NO:2, P3 sequence SEQ ID NO:3, P4 sequence SEQ ID NO:4, P5 sequence SEQ ID NO:5 or with the ribosome recognition site 5'-GGAG-3', 5'-GAAAG-3', 5'-GAGGA-3' or 5'-GGGGAG-3' substituted for the 5'-GAGAGA-3' of the P1 sequence, a sequence of 5'-GGGAGA-3' with the P2 sequence, a sequence of 5'-GAAG-3' with the P3 sequence, a sequence of 5 '-AAGGGGGG-3' with the P4 sequence or an AGGAGG with the P5 sequence; the sequence of the exogene is shown as SEQ ID NO. 8, SEQ ID NO. 11 or SEQ ID NO. 14.

Further defined, the promoter sequence is shown as SEQ ID NO. 48, and the sequence of the efflux gene is shown as SEQ ID NO. 8. The invention also provides a recombinant strain containing the recombinant vector for improving the yield of macrolide antibiotics, wherein the recombinant strain is obtained by taking industrial streptomyces icebergensis, streptomyces icebergensis wild type, streptomyces avermitilis (Streptomyces avermitilis) or streptomyces glaucocalycus (Streptomyces cyaneogriseus) as starting bacteria and introducing the recombinant vector into the starting bacteria.

Further defined, the promoter sequence is shown as SEQ ID NO. 47, and the sequence of the efflux gene is shown as SEQ ID NO. 11. The invention also provides a recombinant strain containing the recombinant vector for improving the yield of macrolide antibiotics, wherein the recombinant strain is obtained by taking industrial streptomyces icebergensis, streptomyces icebergensis wild type, streptomyces avermitilis (Streptomyces avermitilis) or streptomyces glaucocalycus (Streptomyces cyaneogriseus) as starting bacteria and introducing the recombinant vector into the starting bacteria.

Further defined, the promoter sequence is shown as SEQ ID NO. 48, and the sequence of the efflux gene is shown as SEQ ID NO. 14. The invention also provides a recombinant strain containing the recombinant vector for improving the yield of macrolide antibiotics, wherein the recombinant strain is obtained by taking industrial streptomyces icebergensis, streptomyces icebergensis wild type, streptomyces avermitilis (Streptomyces avermitilis) or streptomyces glaucocalycus (Streptomyces cyaneogriseus) as starting bacteria and introducing the recombinant vector into the starting bacteria.

The invention also provides application of the recombinant strain in improving the potency and yield of macrolide antibiotics.

The beneficial effects are that: the invention provides a recombinant vector for improving the yield of macrolide antibiotics, which is prepared by genetic engineering reconstruction, and in fermentation production, the feedback inhibition effect of a final product is lightened, and the yields of milbemycins, abamectin and Ni Mo Keding are improved.

Drawings

FIG. 1 is the effect of the efflux module TuPPE on milbemycins potency in Streptomyces icebergensis wild type, wherein a is the design of the efflux module, promoter is Promoter, RBS is ribosome recognition site, effluxpump is efflux gene; b is the effect of constitutive promoter over-expression of the efflux gene on milbemycins titer, wherein the abscissa is the starting strain BC-101-4 and the recombinant strains BCM-tAB 1, BCM-tAB 2, BCM-tAB 6 corresponding to the over-expression of the efflux gene; the ordinate is the total and extracellular potency of milbemycins; c is the effect of the use of efflux modules to fine tune MiltAB2 on milbemycins potency, wherein the abscissa is the use of the efflux modules to overexpress the Promoter (Promoter) and ribosome recognition site (RBS) of the MiltAB2 recombinant vector; the ordinate is the total potency of milbemycins; d is the effect of the use of efflux modules to fine tune MiltAB1 on milbemycins potency, wherein the abscissa is the use of the efflux modules to overexpress the Promoter (Promoter) and ribosome recognition site (RBS) of the MiltAB1 recombinant vector; the ordinate is the total potency of milbemycins; e is the effect of the use of an efflux module to fine tune MiltAB6 on milbemycins potency, wherein the abscissa is the use of the efflux module to overexpress the Promoter (Promoter) and ribosome recognition site (RBS) of the MiltAB6 recombinant vector; the ordinate is the total potency of milbemycins;

FIG. 2 shows the optimal improvement of milbemycins potency by efflux modules, wherein a is the optimal improvement of total and extracellular potency of TuPPE in Streptomyces icebergensis wild type, wherein the abscissa is the starting strain BC-101-4 and the corresponding recombinant strains WTM11c, WTM22d, WTM61c overexpressing the efflux genes, and the ordinate is the total and extracellular potency of milbemycins; b is the optimal improvement of the total and extracellular potency of milbemycins by TuPPE in Streptomyces industrialis BC04, wherein the abscissa is the starting strain BC04 and the corresponding recombinant strains HTM11c, HTM22d, HTM61c overexpressing the efflux genes, and the ordinate is the total and extracellular potency of milbemycins; c is the optimal improving effect of TuPPE on milbemycins yield in Streptomyces icebergensis wild type, wherein the abscissa is the starting strain BC-101-4 and the corresponding recombinant strains WTM11c, WTM22d and WTM61c over-expressing the efflux genes, and the ordinate is the milbemycins yield; d is the optimal improvement effect of TuPPE on milbemycin yield in industrial streptomyces BC04, wherein the abscissa is the starting strain BC04 and the recombinant strains HTM11c, HTM22d and HTM61c corresponding to the over-expressed efflux genes, and the ordinate is the milbemycin yield;

FIG. 3 is a diagram of the polyketone skeleton of different 16-membered macrolide antibiotics, wherein the grey scale places are skeletons with the same structure of the three macrolides;

FIG. 4 shows the universality of the efflux module TuPPE in terms of increasing the potency of other macrolides, wherein a is the optimal improvement effect of TuPPE on the total potency and extracellular potency of avermectin in Streptomyces avermitilis, wherein the abscissa is the starting strain SAV and the corresponding efflux gene overexpressing recombinant strain, and the ordinate is the total potency and extracellular potency of avermectin; b is the optimal improvement of the total and extracellular titers of TuPPE on Ni Mo Keding in Streptomyces coelicolor, wherein the abscissa is the starting strain Nem and the corresponding efflux gene overexpressing recombinant strain, and the ordinate is the total and extracellular titers of Ni Mo Keding.

DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION

Streptomyces icechenensis wild-type BC-101-4 (Streptomyces bingchenggensis), a strain described in Wang et al, appl Microbiol Biotechnol (2020) 104:2935-2946DOI 10.1007/s00253-020-10410-8.

Streptomyces icebergii BC04 (Streptomyces bingchenggensis), which is described in Zhang et al, microb Cell face (2016) 15:152DOI 10.1186/s12934-016-0552-1.

Streptomyces avermitilis (Streptomyces avermitilis), streptomyces avermitilis NEAU1069, is described in Wang et al journal of antibiotics (2011) 64:591-594DOI 10.1038/ja.2011.48.

Streptomyces coelicolor (Streptomyces cyaneogriseus), streptomyces coelicolor NMWT1, a strain described in Li et al, china Life Sciences (2019) 15:152DOI 10.1007/s11427-018-9442-9.

pSET152T integrates with the E.coli-Streptomyces shuttle vector, pSET152 is a commercial plasmid, pSET152T is a pSET152 plasmid with a terminator sequence.

Coli JM109 was used as the host for all plasmid constructions.

ET12567 (puc 8002) was used for joint transfer of streptomyces with escherichia coli, a commercial strain.

Example 1.

1. Construction of macrolide efflux modules

All relevant promoters and efflux genes were amplified using the Streptomyces icebergii BC-101-4 Genome (accession number Genome ID: CP002047.1 on GenBank) as a template, wherein the components of the macrolide efflux module include the promoter, ribosome recognition site and efflux gene. The combined fragment of the promoter and the ribosome recognition site is PiRj, wherein Pi is a promoter P1 (the sequence is shown as SEQ ID NO: 1), P2 (the sequence is shown as SEQ ID NO: 2), P3 (the sequence is shown as SEQ ID NO: 3), P4 (the sequence is shown as SEQ ID NO: 4), P5 (the sequence is shown as SEQ ID NO: 5), rj is a ribosome recognition site Rn (Rn is the original ribosome recognition site sequence of each promoter), ra (5 '-GGAG-3'), rb (5 '-GAAAG-3'), rc (5 '-GAGGA-3'), rd (5 '-GGAG-3') and Streptomyces fraxinus BC-101-4 genome are used as templates, and PiRj fragments (i represents 1-5,j and n, a, b, c and d) are obtained by amplification of a pair of PiRj-R primers.

A fragment of the efflux gene MiltAB1 was cloned from genomic DNA of Streptomyces icebergii BC-101-4 using a primer pair M1-F/M1-R (M1-F: 5'-GGACTAGTGTGATCGAAGTGCGCGACCTCA-3', SEQ ID NO: 6; M1-R:5'-GCTCTAGAGGATCCTCAAGGGTCGCGGCGGCGCAG-3', SEQ ID NO: 7). The efflux Gene MiltAB1 comprises 2 Gene fragments, accession numbers on GenBank are Gene ID 11615354 (encoding transmembrane protein) and 11615355 (encoding ATP binding protein), and the nucleotide sequence of the efflux Gene MiltAB1 is shown as SEQ ID NO 8.

The fragment of the efflux gene MiltAB2 was cloned from the genomic DNA of Streptomyces icebergii BC-101-4 using the primer pair M2-F/M2-R (M2-F: 5'-GGACTAGTATGATCGAAGCTCGTGAGCTG-3'; SEQ ID NO: 9; M2-R: 5'-GCTCTAGAGGATCCTCAGGCGTCGGTCCGCACGA-3'; SEQ ID NO: 10). The efflux Gene MiltAB2 comprises 2 Gene fragments, accession numbers on GenBank are Gene ID 11613875 (encoding transmembrane protein) and 11613876 (encoding ATP binding protein), and the nucleotide sequence of the efflux Gene MiltAB2 is shown as SEQ ID NO. 11.

A fragment of the efflux gene MiltAB6 was cloned from genomic DNA of Streptomyces icebergii BC-101-4 using a primer pair M6-F/M6-R (M6-F: 5'-GGACTAGTGTGAGCGACCCAGGGATCGTCG-3', SEQ ID NO: 12; M6-R:5'-GCTCTAGAGGATCCCTAGGTGTCGCGCATGCGCAGCAG-3', SEQ ID NO: 13). The efflux Gene MiltAB6 comprises 3 Gene fragments, and accession numbers on GenBank are respectively Gene ID 11607422 (encoding transmembrane protein), 11607423 (encoding transmembrane protein) and 11607424 (encoding ATP binding protein), and the nucleotide sequence of the efflux Gene MiltAB6 is shown as SEQ ID NO: 14.

2. Construction of recombinant vector of macrolide efflux Module

Plasmid pSET152T was digested with EcoRI and XbaI to give LpSET152T (linear pSET152T vector) as the backbone for construction of the subsequent plasmid. The combined fragment PiRj of the promoter and the ribosome recognition site obtained in the step one was digested with EcoRI and SpeI and the fragment was recovered by gel.

The combined fragment PiRj specifically comprises a fragment P1R1 amplified by a primer P1R1-F/P1R 1-R; the P1Ra is amplified by using a primer P1R1-F/P1 Ra-R; p1Rb is amplified by using a primer P1R1-F/P1 Rb-R; p1Rc is amplified by using a primer P1R1-F/P1 Rc-R; p1Rd is amplified by using a primer P1R1-F/P1 Rd-R; P2R2 is obtained by amplification of a primer P2R2-F/P2R 2-R; the P2Ra is amplified by using a primer P2R2-F/P2 Ra-R; p2Rb is amplified by using a primer P2R2-F/P2 Rb-R; p2Rc is amplified by using a primer P2R2-F/P2 Rc-R; p2Rd is amplified by using a primer P2R2-F/P2 Rd-R; P3R3 is obtained by amplification of a primer P3R3-F/P3R 3-R; p3Ra3 is amplified by using a primer P3R3-F/P3 Ra-R; p3Rb is amplified by using a primer P3R3-F/P3 Rb-R; p3Rc is amplified by using a primer P3R3-F/P3 Rc-R; p3Rd is amplified by using a primer P3R3-F/P3 Rd-R; P4R4 is amplified by using a primer P4R4-F/P4R 4-R; the P4Ra is amplified by using a primer P4R4-F/P4 Ra-R; p4Rb is amplified by using a primer P4R4-F/P4 Rb-R; p4Rc is amplified by using a primer P4R4-F/P4 Rc-R; p4Rd is amplified by using a primer P4R4-F/P4 Rd-R; P5R5 is amplified by using a primer P5R5-F/P5R 5-R; the P5Ra is amplified by using a primer P5R5-F/P5 Ra-R; p5Rb is amplified by using a primer P5R5-F/P5 Rb-R; p5Rc is amplified by using a primer P5R5-F/P5 Rc-R; p1Rd was amplified using primers P5R5-F/P5 Rd-R. The primer sequence table is shown in table 1.

TABLE 1 primer sequence listing

And (3) carrying out enzyme digestion and gel combination on the purified exogene fragment MiltAB1 obtained in the step one by using SpeI and XbaI to recover corresponding fragments, connecting a combined fragment PiRj of a double-enzyme-digested promoter and a ribosome recognition point with the exogene fragment MiltAB1 obtained after double enzyme digestion and a plasmid skeleton LpSET152T by using T4 ligase to obtain recombinant vectors, all converting the recombinant vectors into competent E.coli, coating, picking and cloning the recombinant vectors to a small test tube for culture, extracting the recombinant plasmids by using a plasmid extraction kit, carrying out enzyme digestion verification and sequencing verification after electrophoresis detection, and obtaining the recombinant vector pMiltAB1ij related to the corresponding exogene MiltAB 1.

And (3) carrying out enzyme digestion and gel combination on the purified exogene fragment MiltAB2 obtained in the step one by using SpeI and XbaI to recover corresponding fragments, connecting a combined fragment PiRj of a double-enzyme-digested promoter and a ribosome recognition point with the exogene fragment MiltAB2 obtained after double enzyme digestion and a plasmid skeleton LpSET152T by using T4 ligase to obtain recombinant vectors, all converting the recombinant vectors into competent E.coli, coating, picking and cloning the recombinant vectors to a small test tube for culture, extracting the recombinant plasmids by using a plasmid extraction kit, carrying out enzyme digestion verification and sequencing verification after electrophoresis detection, and obtaining the recombinant vector pMiltAB2ij related to the corresponding exogene MiltAB 2.

And (3) carrying out enzyme digestion and gel combination on the purified exogene fragment MiltAB6 obtained in the step one by using SpeI and XbaI to recover corresponding fragments, connecting a combined fragment PiRj of a double-enzyme-digested promoter and ribosome recognition points with the exogene fragment MiltAB6 obtained after double enzyme digestion and a plasmid skeleton LpSET152T by using T4 ligase to obtain recombinant vectors, all converting the recombinant vectors into competent E.coli, coating, picking and cloning the recombinant vectors to a small test tube for culture, extracting the recombinant plasmids by using a plasmid extraction kit, carrying out enzyme digestion verification and sequencing verification after electrophoresis detection, and obtaining the recombinant vector pMiltAB6ij related to the corresponding exogene MiltAB6.

3. Construction of recombinant bacteria of macrolide efflux module recombinant vector

The recombinant vector pMiltAB1ij prepared in the second step is respectively introduced into Streptomyces icebergensis BC-101-4 through a joint transfer experiment to obtain recombinant strain WTM1ij capable of synthesizing milbemycin, the recombinant vector pMiltAB2ij prepared in the second step is respectively introduced into Streptomyces icebergensis BC-101-4 through a joint transfer experiment to obtain recombinant strain WTM2ij capable of synthesizing milbemycin, and the recombinant vector pMiltAB6ij prepared in the second step is respectively introduced into Streptomyces icebergensis BC-101-4 through a joint transfer experiment to obtain recombinant strain WTM6ij capable of synthesizing milbemycin.

P2Rd, the sequence obtained by substituting the ribosome recognition site Rd,5'-GGGGAG-3' for the 5'-GGGAGA-3' of the P2 sequence is shown as SEQ ID NO. 47.

The recombinant vector pMiltAB11c prepared in the second step is introduced into Streptomyces icebergensis BC04 through a conjugative transfer experiment to obtain a recombinant strain HTM11c capable of synthesizing milbemycins, the recombinant vector pMiltAB22d prepared in the second step is introduced into Streptomyces icebergensis BC04 through a conjugative transfer experiment to obtain a recombinant strain HTM22d capable of synthesizing milbemycins, and the recombinant vector pMiltAB61c prepared in the second step is introduced into Streptomyces icebergensis BC04 through a conjugative transfer experiment to obtain a recombinant strain HTM61c capable of synthesizing milbemycins.

P1Rc: the ribosome recognition site Rc,5'-GAGGA-3' replaces the 5'-GAGAGA-3' of the P1 sequence to obtain a sequence shown in SEQ ID NO. 48.

The recombinant vector pMiltAB11c prepared in the second step is guided into streptomyces avermitilis SAV through a joint transfer experiment to obtain a recombinant strain SMT11c capable of synthesizing avermectin, the recombinant vector pMiltAB22d prepared in the second step is guided into streptomyces avermitilis SAV through a joint transfer experiment to obtain a recombinant strain SMT22d capable of synthesizing avermectin, and the recombinant vector pMiltAB61c prepared in the second step is guided into streptomyces avermitilis SAV through a joint transfer experiment to obtain a recombinant strain SMT61c capable of synthesizing avermectin.

The recombinant vector pMiltAB11c prepared in the second step is introduced into Streptomyces coelicolor Nem through a conjugative transfer experiment to obtain a recombinant strain NMT11c capable of synthesizing Ni Mo Keding, the recombinant vector pMiltAB22d prepared in the second step is introduced into Streptomyces coelicolor Nem through a conjugative transfer experiment to obtain a recombinant strain NMT22d capable of synthesizing Ni Mo Keding, and the recombinant vector pMiltAB61c prepared in the second step is introduced into Streptomyces coelicolor Nem through a conjugative transfer experiment to obtain a recombinant strain NMT61c capable of synthesizing Ni Mo Keding.

Comparative example 1.

1. The recombinant vector construction procedure of step two in example 1 was repeated, except that the promoter described in this comparative example was a constitutive promoter, phrdB, to control the expression of the efflux genes MiltAB1, miltAB2 and MiltAB3, respectively. The method comprises the following steps:

the plasmid pSET152 was amplified using the PhrdBmilR (described in Zhang et al, microb Cell face (2016) 15:152DOI 10.1186/s 12934-016-0552-1) as template, the double digested outer gene fragment and the double digested outer gene fragment were finally ligated with T4 ligase using the primer pair PhrdB-F/PhrdB-R (PhrdB-F: 5'-CGGAATTCTCTAGACCGCCTTCCGCCG-3': SEQ ID NO: 45; phrdB-R: 5'-GGACTAGTGAACAACCTCTCGGAACGTTGAAAA-3': SEQ ID NO: 46) and the plasmid was extracted using EcoRI and SpeI double digested hrdB promoters and the recovered digested products were purified, the purified outer gene fragment obtained in step one of example 1, miltAB2, miltAB3 was digested with SpeI and XbaI and glued, finally the double digested outer gene fragment and the backbone LpSET152T were ligated, transformed, coated, the clone was picked up and extracted using the extraction kit, and digested and verified to obtain the plasmid pMtAB composition pMtAB 6, pMtAB control gene.

2. The procedure of example 1, step three, was repeated, except that the recombinant vectors described in this comparative example were pMiltAB1, pMiltAB2, pMiltAB6. The method comprises the following steps:

plasmids pMiltAB1, pMiltAB2 and pMiltAB6 were introduced into Streptomyces icebergensis BC-101-4, respectively, by the method of conjugal transfer, to give recombinant strains BCM iltAB1, BCM iltAB2 and BCM iltAB6, which can synthesize milbemycins, according to the method of step three of example 1.

Plasmids pMiltAB1, pMiltAB2 and pMiltAB6 were introduced into Streptomyces avermitilis SAV by conjugative transfer, respectively, by the method described in step three of example 1, to give recombinant strains SMH1, SMH2 and SMH6 which can synthesize avermectin.

Plasmids pMiltAB1, pMiltAB2 and pMiltAB6 were introduced into Streptomyces coelicolor Nem, respectively, by the method of conjugal transfer, to give recombinant strains NMH1, NMH2 and NMH6 capable of synthesizing Ni Mo Keding, according to the method of step three of example 1.

The following experiment was used to verify the experimental effect: fermentation and HPLC detection verify the change of macrolide antibiotics potency in recombinant bacteria.

The recombinant strains WTM1ij, WTM2ij, WTM6ij, HTM11c, HTM22d, HTM61c prepared in step three of example 1 and the recombinant strains BCMILTAB1, BCMILTAB2 and BCMILTAB6 prepared in step two of comparative example 1 were used, after culturing for 9 days on SKYM medium at 28℃about 1 square centimeter of spores were scraped and inoculated to Streptomyces icebergii SSPY seed culture solution, after culturing for 46 hours at 28℃at 250rpm, 6% of the inoculated amount was inoculated to fermentation medium, and after culturing for 9 days at 28℃at 250rpm, the fermentation broth was harvested and subjected to liquid phase detection.

Using SMT11c, SMT22d and SMT61c prepared in step three of example 1 and SMH1, SMH2 and SMH6 prepared in comparative example 2, after culturing for 7 days at 28℃on MS medium, about 1 square centimeter of spores were scraped and inoculated into Streptomyces avermitilis seed medium, after culturing for 40 hours at 28℃at 250rpm, 6% of the inoculum size was inoculated into fermentation medium, after culturing for 10 days at 28℃at 250rpm, the fermentation broth was taken and subjected to liquid phase detection.

Using NMT11c, NMT22d and NMT61c prepared in step three of example 1 and NMH1, NMH2 and NMH6 prepared in comparative example 2, after culturing on ISP3 medium at 28℃for 9 days, about 1 square centimeter of spores were scraped and inoculated to Streptomyces coelicolor seed medium, after culturing at 28℃for 46 hours at 250rpm, 6% of the inoculum size was inoculated to fermentation medium, after culturing at 28℃for 9 days at 250rpm, the fermentation broth was taken and subjected to liquid phase detection.

The extracellular oxytocin detection method of the corresponding secondary metabolite comprises the following steps: detection of extracellular milbemycins, 2ml of fermentation broth was centrifuged at 12000 Xg for 15min, and 500. Mu.L of supernatant was added with three volumes of ethanol to extract extracellular milbemycins. Then, the mixture was shaken for 30 minutes, centrifuged at 12000 Xg for 15 minutes at high speed, and the supernatant was collected and subjected to HPLC. The method for detecting extracellular ni Mo Keding is the same as the method for treating milbemycins. The detection method of the extracellular avermectin is to use methanol to replace ethanol to carry out the same treatment on the supernatant of the fermentation liquor.

The specific detection methods for the growth and fermentation of the streptomyces icechensinensis and recombinant bacteria thereof, the streptomyces avermitilis and recombinant bacteria thereof, the streptomyces bluish and recombinant bacteria thereof and the solid culture medium, the seed liquid, the fermentation liquid formula and the corresponding secondary metabolites are all described in Jin et al Synthh System Biotechnol (2020) 5:214-221DOI 10.1016/j.synbio.2020.07.001.

Analysis of results: the exotic module constructed by using five different promoters, nine ribosome recognition sites and three groups of exotic genes as element libraries can effectively improve the extracellular potency and the corresponding total potency of milbemycins in streptomyces glacialis (the element arrangement of the exotic module is shown as a in figure 1). In particular, the results show that the effect of improving milbemycin potency is better than the constitutive promoter PhrdB when the orthogonal combination of promoter and ribosome recognition site is reached, wherein the ribosome recognition site Rc and the efflux gene MiLAB1 are matched with the promoter P1; when the ribosome recognition site Rd and the efflux gene MiLAB2 are matched by using the promoter P2; milbemycins titers reached 1807mg/L,1958mg/L and 1767mg/L when the ribosome recognition site Rc was matched with promoter P1 and the efflux gene MiLAB6, respectively (results shown as b-e in FIG. 1). Wherein the optimal recombinant strain WTM22d has 12.3 percent higher milbemycin titer than the strain in which the constitutive promoter PhrdB is used for over-expressing the exogenes, and the extracellular milbemycin titer is improved by 23.6 percent. The total yield of milbemycins reaches 24.4mgA3/A4/g sucrose, which is 44.4% higher than that of the wild-type strain (the result is shown as a in FIG. 2). The results indicate that the use of macrolide efflux modules is of great importance for increasing milbemycins potency and that the combined expression elements are better than constitutive promoters.

The invention introduces the constructed macrolide efflux module into industrial streptomyces ice city BC04, streptomyces Avermitilis (SAV) and streptomyces bluish gray mould (Nem) through joint transfer to construct corresponding engineering strains. The fermentation results showed that the total titers were increased by 24.2%, 18.4% and 14.7% and the extracellular titers were also increased by 3.7, 2.7 and 2.3-fold, respectively, compared to BC04 by the strains HTM22d, HTM11c and HTM61c, in which TuPPE modules were introduced into BC04 (results shown as b-d in fig. 2). Wherein the total yield of HTM22d reached 37.3mgA3/A4/g sucrose was increased by 24.3% over the starting strain (results shown as d in FIG. 2).

The efflux proteins responsible for substrate recognition generally possess a certain substrate breadth, and in view of the similarity of the polyketide frameworks of macrolide antibiotics (as shown in fig. 3), the macrolide efflux modules are also introduced into streptomyces avermitilis and streptomyces coelicolor by conjugation transfer. The potency of avermectin B1a in SMT11c, SMT22d and SMT61c was increased by 38.4% to 4829.7mg/L,27.8% to 4488.3mg/L and 53% to 5373.5mg/L, respectively, compared to SAV (results shown as a in FIG. 4). Correspondingly, the extracellular titers were increased by 2.99-fold, 2.36-fold and 3.34-fold, respectively. The increase in potency of ni Mo Keding in streptomyces coelicolor NMT22d was 41% to 482.6mg/L, NMT11c and NMT61c gave an increase in total potency of 17.3% and 10.6%, respectively (results shown as b in fig. 4). Meanwhile, the extracellular titers of the corresponding strains are respectively improved by 2.4 times, 3.1 times and 2 times.

The above results demonstrate that: (1) The macrolide efflux module TuPPE provided by the invention can effectively improve the titer and the yield of milbemycins in streptomyces glacialis; (2) The optimal transcription and translation levels of the target genes can be obtained through the orthogonal combination of different over-expression elements, so that metabolic pathways in bacteria can be regulated more timely and appropriately, and the titer of the target metabolites can be effectively improved; (3) The macrolide efflux module TuPPE has a certain substrate broad property, is used for verifying that the titers of the other two sixteen-membered macrolide antibiotics avermectin and the Ni Mo Keding are effectively improved, and has a certain universality significance for improving the titers of other macrolide antibiotics.

SEQUENCE LISTING

<110> institute of plant protection of national academy of agricultural sciences

<120> recombinant vector and recombinant bacterium for improving yield of macrolide antibiotics and application thereof

<130>

<160> 48

<170> PatentIn version 3.5

<210> 1

<211> 500

<212> DNA

<213> P1

<400> 1

cacaagtaag cggcgtggtg ttctaattcg gcgaggtcca ggaacggtgc ggggagggtg 60

cctcggtagt cctcccacca tccttggccg cgctgttcgt acgtcatggc cgccagtgag 120

tcgatgagcg cggtgtcggc gcacttgtag aacgccgcga ggcggcgcac gcgctcctcg 180

ctgatcccat agcggcccgt ctcgatgtgg ctgatctgag gttgcccgcc tccgagcagg 240

gcgcccgctt cacgggcggg catgcccgcc gcctcgcgca tcttgcgcag ctcaactccc 300

aggcgcacct ggcgtgctgt ggggttactc ctcggcggca tcgagccctt ctcccggttt 360

gctcatgagt gtgccgctcc accctgccac ggtccacact cggtgtgatg actttcgcgg 420

acatggttgc gacggtgcat gcatggcctc tacggtctgt gatgtaactc tcacgcactg 480

ctcacgagag aagccaccgc 500

<210> 2

<211> 500

<212> DNA

<213> P2

<400> 2

cgaccgagcc gccgactgag ccgccgactg agcacgggcg caggtcggcg gagtcttcct 60

gagtcgcacc gggtcgccct gagtcgtacc gggtcgcgct tgtcgagaca gcgcgaggag 120

cacttttcgg gacaccagtc gccagggtcg cacaggagcg cgaccgcgct ccccgtgcgc 180

ccccagtgac cccccggcgc cccgctccgc gacggccttc aacgcgcccc acgacctgat 240

gcccgtggag ccgcccgcct cgcaccccat ggcgcactcc agggcgtcgc atggcccact 300

ccagggcgcg gtgccgacgg tctcatcggc ggcgctcacc gcgctctcca cgcgccgccc 360

cttgcctctt gtggcgatcc agtggtgaac ttggaccttt tcggatcata agtgggcacc 420

agtgcgccct ggcatcccgt gcctgtcccg ggcacactgc gcagcaggga aaatatggaa 480

gacatgggag agcggcgcgc 500

<210> 3

<211> 500

<212> DNA

<213> P3

<400> 3

ggtcgtagcg aacggtggcg atgaactcgt ccccgaccgt ggcggccagg cccacccggt 60

cgacgtagtc atggtgcgtg aagcggtgca cgtcgcggtc ggagagccgg gggtagggcg 120

cgaagaagcg gtagtacttg gactcgtccg agacccgctc gtagaagctg accaggcgct 180

gcgcgtcgtc agcggtgatg gggcggatcc gggcggtgcc gccgtcgcgg agcaccacat 240

cggcctccca gtgggccggg taggcgtggg tgtcggacgg ctgccgcatg cggccaagac 300

tacggcccgg gcggacatgg gtccgggcgt ccgaatggcg gacacccttg cgttgcgggg 360

aggtgtcgag ggaaagtcca taatcggacc tgtacgggca cggccgggcc tactcggaca 420

tcgttccgga cagacccaga catgcacccc gtatgatatt ggtctagaca acggcaaccc 480

cgcacctgaa gggcaacacc 500

<210> 4

<211> 500

<212> DNA

<213> P4

<400> 4

gccgcggggt gacctggcgg agctggcggg gaagcggatg ttcctgacga gcttccagca 60

gtcgtttccg cgaccggaac tcatctatgg ggaccatgag ttccggcggg cggagaagga 120

cgacacctat cagcgcgtca cgtacgacca cgagctgctg accatcgggg gcgtccccgc 180

gtggctgctg accgtgggcg gcggcctgct ggccgtgccg gccgccgcgc tcacgctgct 240

gatggcggcc aggcggcgca ggcgggcggc gcgtttctgg gggccgggag gcccgcccgg 300

gccgggggac tcaccggggt atccgcagca cctgtcgccg ggtcaggaca gcttgccgtc 360

gtagtgcggg ggcgttgttc atgacgccac cgcacatacg ccaacgacac ttgcccgccc 420

gttcgttgac tggtgggcgg atagatgggt atgtcatgta ctgacggggt cgcgcctcca 480

ttcaccccaa gggggctttc 500

<210> 5

<211> 500

<212> DNA

<213> P5

<400> 5

catcggggag ctgcgcgccg acggcctgcc gaccggtgcg gtcatcatca acatggtgcg 60

accggcgatc ctcgaccacg cggccgtcga cgccgccgcc aacggccggc gcgccgccgt 120

cgccaaggcc ctgtcccagg cggggctggg cggtgcgcgc cgcggtgggc tcgccgagcg 180

gctggtggac ccgctgctgg agcaggcccg tgagcacgcg gagcgggtcg ccctggagcg 240

ggcgcagcgg gcggagctga cgggcctgga gctgcccctg tacgagctgg agctgctcac 300

cgacggcgtc gacctggccg gcctgtaccg gctcgctacg gatctgcgta agcagtggcc 360

gatgtgagcc gcacgggcga cggcggcgac acgagcggcg cgacacgagc ggcgcaatcc 420

acaccatcag cgcaatcggc atgaacggta cgagcgggcg gtacgcgtcg tacgcgccgt 480

acgcaggagg cggcagaagc 500

<210> 6

<211> 30

<212> DNA

<213> M1-F

<400> 6

ggactagtgt gatcgaagtg cgcgacctca 30

<210> 7

<211> 35

<212> DNA

<213> M1-R

<400> 7

gctctagagg atcctcaagg gtcgcggcgg cgcag 35

<210> 8

<211> 1700

<212> DNA

<213> MiltAB1

<400> 8

gtgatcgaag tgcgcgacct cagcaagaag tacgggacca ccaccgcggt cgaccggctg 60

tccttcaccg tgcggccagg ccaggtgacc gggttcctcg ggccgaacgg ggcgggaaag 120

tccaccacga tgcggatgat gctggacctc gaccgcccca ccacgggcca tgtcctcatc 180

gacggcgagc gctatcggcg cctgtccgat ccgctgcgcc gggtcggggc tctgctggag 240

gccagggcgg tgcacggcgg ccgcagcgtg tacgacaccc tgcgatggcc ggcccgcagc 300

aaccgcatcc ccgaggcgcg ggtgcgcgag gtgctggagc tggtcgggct ggcgggcgtg 360

gcccaccagc gggccaaggg cctctcactc ggcatggccc agcggctcgg tatcgccgcg 420

gcgctgctcg gcgatccgcc ggtgctgctg ttcgacgaac cggtcaacgg ccttgacccc 480

gaggggatcc tctggatccg taacctgatg aaggacctgg ccgcggaggg ccggacggtg 540

ttcgtctcca gccatctgat gagcgagatg gcgctcaccg cggaacacct catcgtcatc 600

gggcgcggca ggctgctcgc ggacaccacc gtagctgcgt tcatcgaggc caactcccgc 660

tcctgtgtgc tgatccgcac gcccgagccg gatcggatgc gcgccgcgct ggcgggcgtg 720

ggcgtccggg tggagcgggc ggccgacggg gcgctggagg cgtacgggac gcgggccgcg 780

gcggtcggcg agctggcggc ggcccagggt ctgacggtgc acgaggtgag cacgcggcag 840

gcctcgctcg aagaggcgtt catgcggctc acaggcgagg ccgccgaaca ccgggcggga 900

ggtgcgcgat gagggacgcg gcccgtgtgc gggcggcctt cgccgccgag tggatcaaga 960

tccgtaccgt ccggtcgacg ctgtggaccc tgctgctgtc cctcgtcgtc agcgtcggcc 1020

tcggcatcct cgtcggccac tccatgagcg cgagcttcgc cgggatggac cgggaacggc 1080

aggagaactt cgaccccgtc gaggcgggtt tcctcggcct gaccgtcggc cagatcgccc 1140

tcgtcgtgtt cggtgtgctg cagatcggcg ccgagtacac cagcggcacc atccgcggct 1200

cgcttctcgc ggtgccgcgc cggggggtgt tctacggggc caaggtggcg gccacgatgc 1260

tgaccgcgct ggtgttctcg ctgttcaccg tctacatcac cttcttcgcg gcgcagtggg 1320

cgctcggccc gcagggcgtc tccctcggcg accccggcgt actgcgcgcg accctcggcg 1380

cctgggcgta tctgacgctg atgtgcgcgt tctcgatcgg ggtggccgcg atgctgcgca 1440

gtacggcgct cacgctcgga atcatgatcc cgctgctctt cctcaactcg caggggctcg 1500

gcaatgtgcc gaagatccgg acggtcgcgc agttcctgcc cgaccaggcc ggggcggtga 1560

tgatgcgggt ggtcacggtg gacgagtcgt tcatcaccca ccgggacttc ggcccgggga 1620

ccgcgctggt gatcctgctg gcctggacgg cggcggcgct cgtcgggggc ctcatggcgc 1680

tgcgccgccg cgacccttga 1700

<210> 9

<211> 29

<212> DNA

<213> M2-F

<400> 9

ggactagtat gatcgaagct cgtgagctg 29

<210> 10

<211> 34

<212> DNA

<213> M2-R

<400> 10

gctctagagg atcctcaggc gtcggtccgc acga 34

<210> 11

<211> 1829

<212> DNA

<213> MiltAB2

<400> 11

atgatcgaag ctcgtgagct gacgaagcgg tacggcgaca agacggtcgt cgacaccttg 60

agcttcaccg tcaagcccgg tgaggtgacc ggcttcctcg gccccaacgg cgcgggcaag 120

tccaccacga tgcgcatgat cgtcggcctg gacactccca ccaagggctc ggtcaccgtg 180

ggcggtcgct cctacgccaa gcacgccgcc ccgctgcacg agatcggcac cctgctggag 240

gccaagtccg tccaccccgg gcgcagcgcc ttcaaccacc tgatggcgct cgcgtacacc 300

cacggcattc cgcgccgccg ggtggaggag gtcatcgagc tggccgggct gacgagcgtg 360

gccggcaagc gcgtgggcgc cttctccctc ggcatgggcc agcggctcgg catcgcctcg 420

gccctgctcg gcgacccggc gatcgtcatg ctcgacgaac cggtcaacgg cctcgacccc 480

gagggtgtgc tgtgggtgcg caacctcctg cgcgggctgg ccgacgaggg ccgggccgtg 540

atgctctcct cgcatctgat gagtgagacc gcgctgatcg ccgaccatct ggtgatcatc 600

ggacgcggcc ggctgctcgc ggacaccacg gcctgcgact tcacccgcga ggccggtggc 660

ggcggtgtga aggtcgccac caccgaggcc atgaggctgc gcccgctgct ggccggcccc 720

gacgtcacga tcagctcgtc gtccgccgag gaactgctgg tcaccggacg tgacgcccat 780

gagatcgggg cgatcgccgc tcagcacggg gtgccgctgt acgaactcac ccccaaggcc 840

gtgtccctgg aggcggcctt catggacctc acccgcgacg ccgtcgagta ccagagcgcc 900

cccgccggca ccgaacgaaa ggccgcctga tgcccaccac cgcactccac cgcagccggc 960

gcccgggccc gggcaagggc cggaacctct ccgcggcgcc cgagcccaag gtcccggcaa 1020

cgcccaggac ggcctacaag gtgaccggta tccgtgtgct gcgctcggag tgggccaagt 1080

tctggtcgct gcgctccacc tggatcaccc tgggcgtcgc cgtcgtcctg ctgatcctct 1140

tcggggcgat cgcctcgtac acctacagtc ccgacgccgt cgcgaccagc gggccacccg 1200

gcccgggaag ctccgacgtc gacagcgacg ccgtcagtct ggcactgacc ggtgtgtcct 1260

tcgcgcagtt ggccatcggt gtgctcgggg tgctgctgtc cgcgggcgag tacagcaccg 1320

gcatgatccg ctccaccctc gccgcggttc cgcggcggct gccggtcctg tggtccaagg 1380

ccgccgtgat cgggcccatc gccctcgtcc tcaccaccgt cggcgcgctg gccgccttcc 1440

aactgggcgt accgggcctg gacggcgaga agatcgcgct gtccctgggc gacgacggcg 1500

tgctgcgcgc cctggccggc gccggtgtct atctcggcct ggtggccgtg ttcggcgtgg 1560

ccctgggcgt gctgatccgc tcgtccgccg gggccatcgc ggccctggtc ggcgtgctgc 1620

tcatcctgcc cggtctggcc tcgttgctgc ccgactcgtg gtacgacacg ctcagtccct 1680

acttccccag caacgcgggg tcggctgtct acgccctgca ccagtcatcg gacgccctga 1740

cgcccggggc ggggctcgcg gtcttcgccg gctgggtggc gctgaccctc gccggggccg 1800

ccttccggct cgtgcggacc gacgcctga 1829

<210> 12

<211> 30

<212> DNA

<213> M6-F

<400> 12

ggactagtgt gagcgaccca gggatcgtcg 30

<210> 13

<211> 38

<212> DNA

<213> M6-R

<400> 13

gctctagagg atccctaggt gtcgcgcatg cgcagcag 38

<210> 14

<211> 3232

<212> DNA

<213> MiltAB6

<400> 14

gtgagcgacc cagggatcgt cgtcgccgga ctgcgcaagc gatatggggc ggccctggcc 60

ctcgacggca tgtccttcac cgtccgcccg gggctggtga ccggcttctt ggggccgaac 120

ggggccggga agtccaccac catgcgggtg atcctcggcc tggacgcggt tgaggcgggc 180

accgcgctca tcgaggggaa gccctaccac agccttcggc acccgctgaa ccatgtcggt 240

tcactgctgg acgcggcggc actgcacccc agccgcagcg ggcgcaacca cctgctgtgg 300

ctggcgcatt cgcagggcct ggccgcgcgt cgggtggacc aggtgatcga gcaggtcggc 360

ctggtcccgg cggcccggcg caaggccggc ggctactcgc tcggcatgcg gcagcggctc 420

gggatcgccg cggccctgct gggcgacccg ccgatcatca tgctcgatga gccgttcaac 480

ggcatggacc ccgacggcat catctggatg cgcggcttcc tgcggtcgtt ggccgctcag 540

ggccgcgccg tgctggtctc cagccacctg atgagcgagg tacaggacac agccgatcat 600

ctcgtcgtgg tcgggcgcgg caaggtcatc gccgacgacg gcgtggccga gctgatcgcg 660

gccgcgtccg ggaaccgggt ggccctgcgg accacggccg ggacacacgc gatgacggtg 720

ctcaggtgtg caggcgcggc cgtggcggcc accggccgcg acaccatcac ggtctccggc 780

ctgcccgcgg accggatcgt gacgctgctc ggcgagagcg cggtgccgtt ctccgaggta 840

tcagcgcacc gcgccaccct tgaggacgtc tacttggaac tcacccgcga cgcggtcgag 900

ttccgcgccg ggacgcccac ggaggtctcg cggtgacccc cactgttacg ccgtaccggt 960

ccggccgggg ggccgggcgg gacggtttcg tgcagttgct gcacgcggag tggaccaagt 1020

tccggacggt cctgggctgg gtgaccggcg tggtggtggc agcactgatg gtggtgctgt 1080

tcgccctgct cgccggggtc agtagcgatc agaagggctc accgcccgtt ccggtcggac 1140

cgggtggtga gccggttacc gacagcttct acttcgtgca ccagccgctg gcgggagacg 1200

gcagcatcac tgtctccgtt tccgcgctca ggagcagcgt ccccaagcgt cccggtgacc 1260

tgcggcccgg catcgtgccg tgggcgaagg ccgggatcgt catcaaggag agcacccgtc 1320

agggatcgcc ctacgcggcg atcatggtca ccagcagcca cggcgtgcgg atgcaggaca 1380

gctacgtcaa cgacacggcg ggcctccccg gtcctgtctc cgccgagtct gtccgccggc 1440

tgcggctgga ccgctcgggc gacgcgatca ccggctatgc ctccgccgac ggcatgcact 1500

ggaccaaggt gggcaccgtg cacgtcagcg ggctcggacc gaccgcgcaa ggcgggctgt 1560

tcgtcgcgtc tccgccttcc gtggatggca tgggcacgcg cggcagtgtg tccacggccg 1620

tcttcgggga tcttcgtatc caggggcgct gggccggtgg caactggaca ggcggccagg 1680

tgggacccga atcccccagc ttctccggct acccgaagaa cacgtcgggt tcgttcacgg 1740

aatccgacgg ccgcctcacg gtgaccggcg ccggcgacat agcgcccgcc gttcgcgaca 1800

ctctgccgac cggcggcacc ctcggagaac tcctcaccgg cacgttcgcc gcgctgatcg 1860

tggtgatcgt cgtgggggcg ctgttcatca ccacggaata ccggaagaac ctgatccatg 1920

taaccctggc cgccggcccg agacggagcc gggtgctggt ggccaaggcg acggtgctgg 1980

ggggcgtcac cttcgtcgcc gggctggcgg gggcggccgt cgcggttccg ctcggcgagc 2040

ggctcgcccg ggccaacggc gtgtacgtct tcccggtgac gtcttcaacc gaactacggg 2100

tggagctcgg gatcgcggcg ctgctcgcga ccgcctcggt cctggccctc gccgtcggca 2160

ccatattccg gcacagtgcc ggcgcggtca ccaccgtcat cgtggccatc gtgctgccct 2220

acatcctgat cgccatcccg ttcatacccg cgagcgtgtc gaactggctg gcccgggtga 2280

ccccgggcgc ggccttcgcc gtccagcaga cgcttgtgca gtatcgccag gtcgccagca 2340

attacacgcc ctacaacggc tattacccgc tggcaccgtg ggcagggttc gccgtcctgg 2400

caggctacgc ggtggcaagc ctggccgcag ccgccgtcct tctccgcagg agggacgcat 2460

gagaccggcc ctgcacgcgg aatggacgaa gctacggacc gtcaccagcc ctctctggct 2520

gctgctcggc atgatcgcgg cgaccgtggc cctgagcgcc ggcgcgacct cggtggtgac 2580

atgcgcgtcc gccggctgcg gcgatatgac caagctcagc ctcatcggcg tcctgctggg 2640

ccaggcgctg gtcgccatcc tggccgtact ggtcatcgca ggcgagtacg gcacgggcat 2700

gatccgcacc accctggcgg cgacaccgca tcgggccacc gtcctcgcgg ccaaagccgt 2760

caccctcacc gggatcgtgg ccgcggccgg gaccatcgcg gttctcgggt cgctggcggc 2820

tgggcggctc ctcctgcccg gccacgcctt cacgaccacc cgtggccacc cgcccctgtc 2880

cctgaccgac tggcccacgc tgcgtgcggc cttcgggtcg atcctctacc tgaccctgat 2940

cgccctgctc agcctcggcg tcgccaccat cgtgcgggac tccgcgacca gtatcgggat 3000

cgtcctcggc ctgctttacc tggtccccgt cctctcccag atgatcggca atccgcactg 3060

gcagcgcctg ctccagcgga tcgggccgat gagcgccggg ctcgccgtcc aggccaccac 3120

cgacatccgc agcctgccca ttggcccctg ggccggtctc ggcgtcaccg ccggatgggc 3180

cgccgcggcg ctcttggccg gcggcctgct gctgcgcatg cgcgacacct ag 3232

<210> 15

<211> 31

<212> DNA

<213> P1R1-F

<400> 15

cggaattcca caagtaagcg gcgtggtgtt c 31

<210> 16

<211> 45

<212> DNA

<213> P1R1-R

<400> 16

ggactagtgc ggtggcttct ctcgtgagca gtgcgtgaga gttac 45

<210> 17

<211> 43

<212> DNA

<213> P1Ra-R

<400> 17

ggactagtgc ggtggctctc cgtgagcagt gcgtgagagt tac 43

<210> 18

<211> 44

<212> DNA

<213> P1Rb-R

<400> 18

ggactagtgc ggtggctctt tcgtgagcag tgcgtgagag ttac 44

<210> 19

<211> 44

<212> DNA

<213> P1Rc-R

<400> 19

ggactagtgc ggtggcttcc tcgtgagcag tgcgtgagag ttac 44

<210> 20

<211> 45

<212> DNA

<213> P1Rd-R

<400> 20

ggactagtgc ggtggctctc cccgtgagca gtgcgtgaga gttac 45

<210> 21

<211> 32

<212> DNA

<213> P2R2-F

<400> 21

cggaattccg accgagccgc cgactgagcc gc 32

<210> 22

<211> 45

<212> DNA

<213> P2R2-R

<400> 22

ggactagtgc gcgccgctct cccatgtctt ccatattttc cctgc 45

<210> 23

<211> 43

<212> DNA

<213> P2Ra-R

<400> 23

ggactagtgc gcgccgcctc catgtcttcc atattttccc tgc 43

<210> 24

<211> 44

<212> DNA

<213> P2Rb-R

<400> 24

ggactagtgc gcgccgcctt tcatgtcttc catattttcc ctgc 44

<210> 25

<211> 44

<212> DNA

<213> P2Rc-R

<400> 25

ggactagtgc gcgccgctcc tcatgtcttc catattttcc ctgc 44

<210> 26

<211> 45

<212> DNA

<213> P2Rd-R

<400> 26

ggactagtgc gcgccgcctc cccatgtctt ccatattttc cctgc 45

<210> 27

<211> 30

<212> DNA

<213> P3R3-F

<400> 27

cggaattcgg tcgtagcgaa cggtggcgat 30

<210> 28

<211> 41

<212> DNA

<213> P3R3-R

<400> 28

ggactagtgg tgttgccctt caggtgcggg gttgccgttg t 41

<210> 29

<211> 41

<212> DNA

<213> P3Ra-R

<400> 29

ggactagtgg tgttgccctc caggtgcggg gttgccgttg t 41

<210> 30

<211> 42

<212> DNA

<213> P3Rb-R

<400> 30

ggactagtgg tgttgccctt tcaggtgcgg ggttgccgtt gt 42

<210> 31

<211> 42

<212> DNA

<213> P3Rc-R

<400> 31

ggactagtgg tgttgcctcc tcaggtgcgg ggttgccgtt gt 42

<210> 32

<211> 43

<212> DNA

<213> P3Rd-R

<400> 32

ggactagtgg tgttgccctc cccaggtgcg gggttgccgt tgt 43

<210> 33

<211> 29

<212> DNA

<213> P4R4-F

<400> 33

cggaattcgc cgcggggtga cctggcgga 29

<210> 34

<211> 40

<212> DNA

<213> P4R4-R

<400> 34

ggactagtga aagccccctt ggggtgaatg gaggcgcgac 40

<210> 35

<211> 38

<212> DNA

<213> P4Ra-R

<400> 35

ggactagtga aagcctccgg ggtgaatgga ggcgcgac 38

<210> 36

<211> 39

<212> DNA

<213> P4Rb-R

<400> 36

ggactagtga aagcctttcg gggtgaatgg aggcgcgac 39

<210> 37

<211> 39

<212> DNA

<213> P4Rc-R

<400> 37

ggactagtga aagctcctcg gggtgaatgg aggcgcgac 39

<210> 38

<211> 40

<212> DNA

<213> P4Rd-R

<400> 38

ggactagtga aagcctcccc ggggtgaatg gaggcgcgac 40

<210> 39

<211> 31

<212> DNA

<213> P5R5-F

<400> 39

cggaattcca tcggggagct gcgcgccgac g 31

<210> 40

<211> 44

<212> DNA

<213> P5R5-R

<400> 40

ggactagtgc ttctgccgcc tcctgcgtac ggcgcgtacg acgc 44

<210> 41

<211> 42

<212> DNA

<213> P5Ra-R

<400> 41

ggactagtgc ttctgccgct ccgcgtacgg cgcgtacgac gc 42

<210> 42

<211> 43

<212> DNA

<213> P5Rb-R

<400> 42

ggactagtgc ttctgccgct ttcgcgtacg gcgcgtacga cgc 43

<210> 43

<211> 43

<212> DNA

<213> P5Rc-R

<400> 43

ggactagtgc ttctgccgtc ctcgcgtacg gcgcgtacga cgc 43

<210> 44

<211> 44

<212> DNA

<213> P5-Rd-R

<400> 44

ggactagtgc ttctgccgct ccccgcgtac ggcgcgtacg acgc 44

<210> 45

<211> 27

<212> DNA

<213> PhrdB-F

<400> 45

cggaattctc tagaccgcct tccgccg 27

<210> 46

<211> 33

<212> DNA

<213> PhrdB-R

<400> 46

ggactagtga acaacctctc ggaacgttga aaa 33

<210> 47

<211> 499

<212> DNA

<213> P1Rc

<400> 47

cacaagtaag cggcgtggtg ttctaattcg gcgaggtcca ggaacggtgc ggggagggtg 60

cctcggtagt cctcccacca tccttggccg cgctgttcgt acgtcatggc cgccagtgag 120

tcgatgagcg cggtgtcggc gcacttgtag aacgccgcga ggcggcgcac gcgctcctcg 180

ctgatcccat agcggcccgt ctcgatgtgg ctgatctgag gttgcccgcc tccgagcagg 240

gcgcccgctt cacgggcggg catgcccgcc gcctcgcgca tcttgcgcag ctcaactccc 300

aggcgcacct ggcgtgctgt ggggttactc ctcggcggca tcgagccctt ctcccggttt 360

gctcatgagt gtgccgctcc accctgccac ggtccacact cggtgtgatg actttcgcgg 420

acatggttgc gacggtgcat gcatggcctc tacggtctgt gatgtaactc tcacgcactg 480

ctcacgagga agccaccgc 499

<210> 48

<211> 500

<212> DNA

<213> P2Rd

<400> 48

cgaccgagcc gccgactgag ccgccgactg agcacgggcg caggtcggcg gagtcttcct 60

gagtcgcacc gggtcgccct gagtcgtacc gggtcgcgct tgtcgagaca gcgcgaggag 120

cacttttcgg gacaccagtc gccagggtcg cacaggagcg cgaccgcgct ccccgtgcgc 180

ccccagtgac cccccggcgc cccgctccgc gacggccttc aacgcgcccc acgacctgat 240

gcccgtggag ccgcccgcct cgcaccccat ggcgcactcc agggcgtcgc atggcccact 300

ccagggcgcg gtgccgacgg tctcatcggc ggcgctcacc gcgctctcca cgcgccgccc 360

cttgcctctt gtggcgatcc agtggtgaac ttggaccttt tcggatcata agtgggcacc 420

agtgcgccct ggcatcccgt gcctgtcccg ggcacactgc gcagcaggga aaatatggaa 480

gacatgggga ggcggcgcgc 500

Claims (4)

1. The recombinant vector is characterized in that a starting vector of the recombinant vector is pSET152T, a promoter and a ribosome recognition site are connected with an efflux gene to obtain an efflux module, and the efflux module is integrated into the starting vector to obtain the recombinant vector, wherein the promoter and the ribosome recognition site are positioned at the upstream of the efflux gene; the sequence of the exogene is shown as SEQ ID NO. 48, the sequence of the promoter sequence and the ribosome recognition site are shown as SEQ ID NO. 8 and SEQ ID NO. 47, the sequence of the exogene is shown as SEQ ID NO. 11 or the sequence of the promoter sequence and the ribosome recognition site are shown as SEQ ID NO. 48, and the sequence of the exogene is shown as SEQ ID NO. 14; the pSET152T is a pSET152 plasmid with a terminator sequence.

2. Use of the recombinant vector of claim 1 for increasing the potency and yield of macrolide antibiotics.

3. A recombinant strain containing the recombinant vector of claim 1, wherein the recombinant strain is prepared from industrial Streptomyces glacialis BC04, streptomyces glacialis wild type and Streptomyces avermitilisStreptomyces avermitilis) Or Streptomyces coelicolorStreptomyces cyaneogriseus) A recombinant strain obtained by introducing the recombinant vector of claim 1 into a starting strain for the starting strain.

4. Use of the recombinant strain of claim 3 for increasing the potency and yield of macrolide antibiotics.